

# Early myocardial damage assessment in dystrophinopathies using $^{99}\text{Tc}^m$ -MIBI gated myocardial perfusion imaging

Li Zhang<sup>1,\*</sup>Zhe Liu<sup>2,\*</sup>Ke-You Hu<sup>3</sup>Qing-Bao Tian<sup>3</sup>Ling-Ge Wei<sup>4</sup>Zhe Zhao<sup>5</sup>Hong-Rui Shen<sup>5</sup>Jing Hu<sup>5</sup>

<sup>1</sup>Department of Cardiovascular Disorders, <sup>2</sup>Department of Geriatrics, The Third Hospital of Hebei Medical University, <sup>3</sup>The Public Health Department, Hebei Medical University, <sup>4</sup>Department of Nuclear Medicine, <sup>5</sup>Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China

\*Li Zhang and Zhe Liu are first coauthors of this paper

**Background:** Early detection of muscular dystrophy (MD)-associated cardiomyopathy is important because early medical treatment may slow cardiac remodeling and attenuate symptoms of cardiac dysfunction; however, no sensitive and standard diagnostic method for MD at an earlier stage has been well-recognized. Thus, the aim of this study was to test the early diagnostic value of technetium  $^{99m}$ -methoxyisobutylisonitrile ( $^{99}\text{Tc}^m$ -MIBI) gated myocardial perfusion imaging (G-MPI) for MD.

**Methods and results:** Ninety-one patients underwent  $^{99}\text{Tc}^m$ -MIBI G-MPI examinations when they were diagnosed with Duchenne muscular dystrophy (DMD) (n=77) or Becker muscular dystrophy (BMD; n=14).  $^{99}\text{Tc}^m$ -MIBI G-MPI examinations were repeated in 43 DMD patients who received steroid treatments for 2 years as a follow-up examination. Myocardial defects were observed in nearly every segment of the left ventricular wall in both DMD and BMD patients compared with controls, especially in the inferior walls and the apices by using  $^{99}\text{Tc}^m$ -MIBI G-MPI. Cardiac wall movement impairment significantly correlated with age in the DMD and BMD groups ( $r_s=0.534$  [ $P<0.05$ ] and  $r_s=0.784$  [ $P<0.05$ ], respectively). Intermittent intravenous doses of glucocorticoids and continuation with oral steroid treatments significantly improved myocardial function in DMD patients ( $P<0.05$ ), but not in BMD patients.

**Conclusion:**  $^{99}\text{Tc}^m$ -MIBI G-MPI is a sensitive and safe approach for early evaluation of cardiomyopathy in patients with DMD or BMD, and can serve as a candidate method for the evaluation of progression, prognosis, and assessment of the effect of glucocorticoid treatment in these patients.

**Keywords:** Duchenne muscular dystrophy, Becker muscular dystrophy, dystrophinopathy,  $^{99}\text{Tc}^m$ -MIBI, cardiomyopathy

## Introduction

Muscular dystrophy (MD) is a spectrum of muscle diseases caused by a mutation in the gene coding the protein, dystrophin,<sup>1</sup> among which Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common types. DMD patients have a completely inactive dystrophin protein and BMD patients have reduced expression of dystrophin, which accounts for the differences between the two types of MD.<sup>2</sup> Patients with DMD and BMD have progressive muscle weakness and muscle atrophy, which usually appears first in calf skeletal muscles and gradually extends to the shoulder girdle muscles, smooth muscles, and cardiac muscles.<sup>3</sup> Respiratory failure and/or heart failure are major causes of death for these patients.<sup>4</sup> Although skin biopsies, DNA testing, and electromyography are well-recognized tests for diagnosing MD, a standard method in the early detection of the pathophysiologic changes in cardiac muscle does not exist.<sup>5,6</sup>

Correspondence: Jing Hu  
Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical University, NO 139, Ziqiang Road, 050051 Shijiazhuang, Hebei Province, People's Republic of China  
Tel +86 311 8860 2057  
Fax +86 311 8860 2057  
Email jinghu201501@sina.com

Several cardiac imaging techniques have been used in clinics for the assessment of myocardial damage in MD patients, including echocardiography, cardiac magnetic resonance imaging (MRI), and nuclear medicine methods. Echocardiography is the most commonly used method, but has poor imaging windows due to scoliosis, lung hyperinflation, and chest wall deformities, which are commonly present in MD patients. In contrast, cardiac MRI has high resolution and sensitivity; however, such examinations take a relatively longer time than echocardiography, which is less tolerated by children, who are the major segment of the population afflicted by MD. Nuclear medicine, the third option in MD diagnosis, has become the major method in evaluating cardiac function by researchers. Thallium-201 chloride-single-photon emission tomography perfusion imaging and technetium 99m-methoxyisobutylisonitrile ( $^{99}\text{Tc}^{\text{m}}$ -MIBI) gated myocardial perfusion imaging (G-MPI) have been reported as valuable methods for evaluating myocardial abnormalities in patients with DMD<sup>7-9</sup> because the combination of perfusion and functional information from these methods can greatly improve the accuracy for detecting myocardial dysfunction.<sup>9,10</sup> The value of nuclear medicine in detecting early cardiac damage in MD patients and the value in assessment of prognosis has yet to be studied. Thus, this study was designed to evaluate the value of  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI in the early diagnosis of MD and use in treatment follow-up and prognosis.

## Methods

### Patients and diagnosis

DMD and BMD patients and control subjects were recruited from the Neuromuscular Disorders Department of the Third Hospital of Hebei Medical University (Hebei Province, People's Republic of China). Control subjects were patients with other neuromuscular disorders that received medical service from the Third Hospital of Hebei Medical University, which were age- and sex-matched with DMD and BMD patients. DMD and BMD diagnoses were excluded in these subjects based on histology reports from tissue biopsies, medical history, and clinical diagnosis according to the diagnostic criteria of DMD and BMD stated in this study. Confirmative diagnoses of DMD and BMD in this study included a combination of evidence of clinical characteristics, creatine kinase level, and skin biopsies. The antibodies used in immunofluorescence staining were anti-dystrophin (-R, -C, and -N) monoclonal antibodies (dilution ratio =1:50; Novocastra, Newcastle upon Tyne, UK) and anti-sarcoglycan ( $-\alpha$ ,  $-\beta$ ,  $-\gamma$ , and  $-\delta$ ) monoclonal antibodies (dilution ratio =1:50; Novocastra). Patients with complete

inactivated dystrophin on sarcolemma were diagnosed as DMD and patients with partial deficiency in dystrophin protein expression were diagnosed as BMD. The exclusion criteria included the presence of valvular heart disease, left ventricular hypertrophy, or other systemic diseases, in addition to MD. This study was approved by the Third Hospital of Hebei Medical University Ethics Committee, and all DMD and BMD patients and controls signed informed consent forms. The experiments conform to the principles outlined in the Declaration of Helsinki.

$^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI and echocardiography data of 77 DMD children (aged 2–13 years) and 14 BMD patients (aged 5–25 years) were obtained. Twenty-eight and 12 age-matched patients served as controls for DMD (control group 1) and BMD (control group 2), respectively. All the subjects recruited in this study were from the neuromuscular database of the Third Hospital of Hebei Medical University between May 2008 and October 2012. Seventy DMD patients received glucocorticoid treatment after the diagnosis for 2 years and  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI was performed again as a follow-up. The follow-up study was not done in BMD patients because glucocorticoid treatment is not the standard for this population.

$^{99}\text{Tc}^{\text{m}}$ -MIBI imaging was acquired 1.5 hours after  $^{99}\text{Tc}^{\text{m}}$ -MIBI injection. The dose was between 148 and 740 MBq, based on the following calculation: children  $^{99}\text{Tc}^{\text{m}}$ -MIBI dose = weight (kg)/70 × dose for adult.<sup>11</sup> The imaging examination was performed using a dual-detector SPECT imaging system (Infinia Hawkeye 4, GE Healthcare, Piscataway, NJ, USA) with low-energy high-resolution collimators. The left ventricular ejection fraction (LVEF), end-diastolic volume (EDV), and end-systolic volume (ESV) were calculated using commercial software packages (Quantitative Gated SPECT, GE Healthcare). Briefly, EDV and ESV were standardized using the patient's own body weight.<sup>12</sup> The SPECT and polar maps were blindly analyzed by two experienced nuclear medicine physicians.

### Data collection and analysis

The range of the myocardial abnormalities was analyzed by seven different regions of the cardiac walls, including the apex, inferior wall, anterior wall, anterolateral wall, inferior-lateral wall, anterior-septal wall, and inferior-septal wall. The degree of the myocardium abnormalities was analyzed by 17 segments based on the polar maps.<sup>13</sup> Basal, mid-cavity, and apical segments, as part of the actual definition of the location of the abnormality along the long axis of the ventricle, were analyzed from the apex to base. The circumferential locations in the basal and mid-cavity were anterior, anterior-septal,

inferior-septal, inferior, inferior-lateral, and anterior-lateral. The remaining segments include apical anterior, apical septal, apical inferior, and apical lateral.

The summed rest score (SRS) was used for the perfusion scores and the analysis of a 17-segment model of the left ventricle with a 5-point scoring system for perfusion defect severity as follows: normal uptake of <sup>99</sup>Tc<sup>m</sup>-MIBI was scored as 0; slightly and moderately decreased uptake was scored as 1 and 2, respectively; severely decreased uptake was scored as 3; and absence of uptake was scored as 4.<sup>14</sup> If there was a disagreement regarding the score of each patient between the two physicians, a final consensus was reached after discussion.

### Statistical analysis

SPSS Version 13.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses in this study. Data that are normally distributed were presented as the mean  $\pm$  standard deviation, while data without a normal distribution were shown as the median and quartile range. Spearman's rank correlation coefficient or Pearson's correlation coefficient was used for correlation analysis. The Kruskal–Wallis test, Friedman test, independent samples *t*-test, and nonparametric test


were used to compare the mean or median between groups. A  $P < 0.05$  was defined as significantly different.

## Results

### Pathologic diagnosis and cardiac function between patients with DMD and BMD and control groups

To diagnose DMD and BMD, all patients received skeletal muscle biopsies and representative images from the DMD, BMD, and control groups as presented in Figure 1. The pathologic changes suggested a phenotypic change in MD. H&E staining revealed normal morphology in controls (Figure 1A). Hematoxylin and eosin (H&E) staining from DMD patients showed muscle fiber diameters of varying sizes with a large number of muscle fibers undergoing degeneration, necrosis, and regeneration (Figure 1E). In addition, there was marked hyperplasia of connective tissues. H&E staining from BMD patients showed scattered muscle fiber degeneration, necrosis, regeneration, and connective tissue proliferation (Figure 1I).

Immunofluorescence staining against different terminal domains of dystrophin, including dystrophin-N, dystrophin-C, and dystrophin-R, showed negative muscle fiber membrane



**Figure 1** Pathological analysis of DMD and BMD patients.

**Notes:** H&E staining showed typical histologic changes of MD, which was further confirmed by immunofluorescent staining of MD markers, including dystrophin-N, -R, and -C (A, E, and I). H&E staining of skin biopsy samples from control, DMD, and BMD groups (B, F, and J). Immunofluorescent staining of protein dystrophin-N in three groups (C, G, and K). Immunofluorescent staining of protein dystrophin-C in three groups (D, H, and L).

**Abbreviations:** H&E, hematoxylin and eosin; MD, muscular dystrophy; DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy.

**Table 1** Characteristics of patients with DMD and BMD, and controls

Statistical index	DMD (n=77)	Control 1 (n=28)	P-value	BMD (n=14)	Control 2 (n=12)	P-value
Age (years)	8.00 (3.50)	7.64±0.49	0.81	13.86±1.918	14±2.25	0.962
Injection dose (MBq)	346±79	328±86	0.665	517±89	496±70	0.785
SRS	6.00 (6.5)	4.61±0.63	0.016	14.71±3.32	5.17±1.08	0.015
LVEF (%)	61.00 (12.5)	62.65±1.32	0.791	59.07±2.65	63.17±1.41	0.188
EDVI	36.35±1.29	34.67±3.63	0.762	53.33±6.76	56.13±5.09	0.539
ESVI	8.32 (9.81)	9.13±2.25	0.179	21.39±4.08	23.11±3.25	0.331
LVEF (%)	62.00 (10.00)	62.79±1.18	0.856	59.64±2.77	62.92±1.22	0.718
EDVI	35.95±1.28	32.15±6.08	0.685	53.30±6.81	56.30±5.77	0.721
ESVI	9.00 (8.71)	8.81 (9.32)	0.823	21.24±4.10	24.03±6.19	0.227

**Notes:** Data are mean ± standard deviation or median (quartile range). P-values are t-test between DMD/BMD and control group 1/control group 2.

**Abbreviations:** n, number of cases; SRS, summed rest score; LVEF, left ventricular ejection fraction; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; Control 1, age-matched control group for DMD; Control 2, age-matched control group for BMD.

staining in DMD and decreased density of staining in muscle fiber membranes in BMD (Figure 1F–H and J–L). The dystrophin staining was normal in controls (Figure 1B–D).

There was no difference in age between DMD or BMD patients and controls after the age-matched strategy in control recruitment ( $P=0.81$  for DMD vs control and  $P=0.962$  for BMD vs control; Table 1). There was a significantly decreased cardiac perfusion score, as reflected by SRS between DMD or BMD patients and control groups ( $P=0.016$  for DMD patients vs control group 1 and  $P=0.015$  for BMD vs control group 2, respectively), indicating a cardiac perfusion deficiency in patients with MD. Decreased SRS was also independently associated with BMD and DMD after adjusting for factors, including age and LVEF from echocardiography ( $P<0.05$ ); however, there was no difference in parameters for cardiac function, including LVEF, EDV index (EDVI), and ESVI index (ESVI), using the Quantitative Gated SPECT method or echocardiography (all  $P>0.05$ ).

## Cardiac function and cardiac perfusion analysis of DMD and BMD patients by $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI

We analyzed the cardiac damage and cardiac functional changes in DMD and BMD patients using  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI. Seven different regions of the cardiac walls, including the apex, inferior wall, anterior wall, anterolateral wall, inferior-lateral wall, anterior-septal wall, and inferior-septal


wall, were analyzed.  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI showed that there were 74 of 77 DMD patients (96.1%) who had cardiac damage with detailed regions involved in the cardiac wall, as summarized in Table 2. Twelve of 14 BMD patients (85.7%) had cardiac damage based on  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI (Table 2). No cardiac wall abnormality on  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI was observed in control groups (data not shown). The seven regional walls of  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI revealed cardiac abnormalities in every wall of the left ventricle in DMD, and was particularly common in the apex and inferior wall of the left ventricle (Figure 2A–C). Myocardial perfusion of the overall left ventricle, left ventricular inferior wall, and apex was greatly reduced in DMD patients (Figure 2A–E for the inferior wall and Figure 2C and F for the apex). A semiquantitative method of 17 segments of G-MPI revealed the presence of cardiac involvement in every segment, and we observed a significant difference among segments in DMD ( $P<0.01$ ). The most severe cardiac impairment was observed at the apical, apical inferior, and apical anterior areas in DMD patients (significance score:  $\alpha' = \alpha/55 = 0.05/55 = 0.0009$ ; Figure 2D–F).

Although the overall left ventricle perfusion was normal in patients with BMD, similar cardiac damage patterns were also observed in the left ventricular inferior wall and apex in patients with BMD (Figure 3A–C). The most severe damage in BMD was located in the mid-inferior and apical inferior areas in these patients (significance score:  $\alpha' = \alpha/55 = 0.05/55 = 0.0009$ ; Figure 3D–F).

**Table 2** Distribution and degree of cardiac damage in the left ventricular wall analyzed by  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI

	Degree of cardiac damage (cases)				Distribution of cardiac damage (cases)						
	Normal	Mild	Moderate	Severe	Inferior	Anterior	Anterol	Inferol	Anteros	Inferos	Apex
DMD	3	28	24	22	45	30	24	10	15	27	55
BMD	2	3	4	5	13	7	2	4	3	6	15


**Abbreviations:**  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI, technetium  $^{99\text{m}}$ -methoxyisobutylisonitrile gated myocardial perfusion imaging; DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; Inferior, inferior wall; Anterior, anterior wall; Anterol, anterolateral wall; Inferol, inferolateral wall; Anteros, antero-septal wall; Inferos, infero-septal wall.



**Figure 2** <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI images from three DMD patients.

**Notes:** <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI myocardial perfusion images from DMD patients showed cardiac damage and reduced myocardial perfusion (A–C). Cross-sections from top-to-bottom of the left ventricle, fractional section, and the horizontal long axis perpendicular to the long axis of the section on <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI examination of three representative DMD patients (D–F). Seventeen-segment targeting bull's-eye diagram with reduced myocardial perfusion on <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI examination of three representative DMD patients.

**Abbreviations:** <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI, technetium 99m-methoxyisobutylisonitrile gated myocardial perfusion imaging; DMD, Duchenne muscular dystrophy.



**Figure 3** <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI images from three BMD patients.

**Notes:** <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI myocardial perfusion images from BMD patients showed cardiac damage and reduced myocardial perfusion (A–C). Cross-sections from top-to-bottom of the left ventricle, fractional section, and the horizontal long axis perpendicular to the long axis of the section on <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI examination of three representative BMD patients (D–F). Seventeen-segment targeting bull's-eye diagram with reduced myocardial perfusion on <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI examination of three representative BMD patients.

**Abbreviations:** <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI, technetium 99m-methoxyisobutylisonitrile gated myocardial perfusion imaging; BMD, Becker muscular dystrophy.

## Effect of hormone therapy on DMD patients evaluated using $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI

Seventy DMD patients received glucocorticoid treatment for 2 years after the initial diagnosis by skin biopsy in this study. A follow-up  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI imaging examination for cardiac damage was performed and compared between DMD patients with or without hormone therapy. Due to the limited number for each age group, we selected the 7- to 10-year-old group ( $n=10-12$ ) for this analysis, which is summarized in Table 3. Cardiac function was greatly protected in each age group after 2 years of hormone treatment compared with the baseline level without hormone therapy (all  $P<0.05$ ; Table 3); however, there was no significant difference in LVEF, EDVI, and ESVI in these DMD patients with and without hormone therapy (all  $P>0.05$ ; Table 3).

## Correlation between SRS and age in DMD and BMD patients

SRS was positively correlated with age in DMD and BMD patients ( $r_s=0.534$  [ $P<0.05$ ] for DMD and  $r_s=0.784$  [ $P<0.05$ ] for BMD; Figure 4A and B). In contrast, the LVEF of DMD and BMD patients was negatively associated with age ( $r_s=-0.627$  [ $P<0.05$ ] for DMD and  $r_s=-0.831$  [ $P<0.05$ ] for BMD; Figure 4C and D). EDVI or ESVI was positively correlated with age ( $r_s=0.396$ ,  $P<0.05$  for EDVI and  $r_s=0.479$ ,  $P<0.05$  for ESVI, respectively) in DMD patients (Figure 4E and F). There was no correlation between EDVI/ESVI and age (data not shown).

## Discussion

DMD and BMD are MD disorders due to a mutation of the *DMD* gene, leading to either inactivation or partial dysfunction of dystrophin protein. Such a defect of dystrophin results in skeletal and cardiac muscle degeneration and necrosis. Patients usually show impaired mobility during the early stage of the disease. As the disease progresses, exercise capacity gradually diminishes, muscles atrophy becomes severe, and patients develop heart and respiratory

failure, which are the leading causes of death for MD patients.<sup>1,3</sup> Because patients do not develop significant cardiac dysfunction-related symptoms during the early stage, dilated cardiomyopathy, life-threatening arrhythmias, and sudden cardiac death occur frequently due to the delayed detection and earlier intervention in DMD and BMD patients.<sup>1,5,6</sup> Therefore, early evaluation and treatment of cardiomyopathy in MD patients are important in an effort to improve the overall survival rate in these patients. In the current study, we evaluated the value of using  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI for cardiac perfusion and cardiac damage assessment in patients with DMD or BMD as an earlier diagnostic method.

We found that earlier changes in myocardial perfusion deficiency could be detected in DMD and BMD patients using  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI when echocardiography parameters, including LVEF, EDVI, and ESVI, were not sensitive to detect myocardial dysfunction, clearly suggesting an earlier detection advantage of the  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI examination compared with traditional imaging methods. Our results are not only consistent with another report involving DMD patients by Fu et al,<sup>9</sup> but has also provided evidence of applying  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI in BMD patients for early cardiac perfusion deficiency for the first time.


Skeletal MD increases with age,<sup>15,16</sup> and cardiac decompensation may ultimately lead to dilated cardiomyopathy during the late stage of DMD and BMD. Nigro et al<sup>17</sup> showed that  $<10\%$  of patients with cardiac dysfunction were younger than 14 years of age, while 80% of these patients developed cardiac decompensation after 4 years of age. Using  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI, we found that children with DMD  $<13$  years of age had a defect in cardiac function judged by EDVI and ESVI. The positive correlation between SRS and aging and the negative correlation between LVEF and aging in our BMD and DMD patients served as additional supporting evidence that was consistent with the finding using  $^{99}\text{Tc}^{\text{m}}$ -labeled human serum albumin radionuclide ventriculography and cardiac MRI studies, which showed a positive correlation;<sup>18,19</sup> however, we did not find a correlation between EDVI/ESVI

**Table 3** Cardiac function in response to hormone therapy analyzed by  $^{99}\text{Tc}^{\text{m}}$ -MIBI GPI

Age (years)	7 (n=10)		8 (n=12)		9 (n=11)		10 (n=10)	
	Hormone therapy Before	After	Before	After	Before	After	Before	After
SRS (score)	4.40±1.58	8.20±4.59*	4.00 (1.75)	6.00 (7.00)*	3.55±1.75	7.27±5.27*	6.30±2.45	10.00±3.68*
LVEF (%)	63.10±5.69	62.20±8.09	62.92±10.54	61.50±9.12	60.00±7.36	58.82±5.74	56.76±7.53	55.80±8.75
EDVI (mL/m <sup>2</sup> )	37.88±8.36	38.05±8.02	38.77±12.65	39.05±12.71	34.61±7.90	34.78±7.64	43.12±8.37	43.54±7.67
ESVI (mL/m <sup>2</sup> )	11.86±6.09	11.76±5.82	8.54 (10.20)	7.70 (10.37)	8.72±4.03	8.69±3.91	15.26±5.56	15.29±5.73

**Notes:** Data are mean ± standard deviation or median (quartile range). \* $P<0.01$  before vs after hormone therapy.

**Abbreviations:** n, number of cases; SRS, summed rest score; LVEF, left ventricular ejection fraction; EDVI, end-diastolic volume index; ESVI, end-systolic volume index;  $^{99}\text{Tc}^{\text{m}}$ -MIBI GPI,  $^{99}\text{m}$ -methoxyisobutylisonitrile gated myocardial perfusion imaging.



**Figure 4** Relationship between cardiac function and age in DMD/BMD patients based on  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI images and statistical analysis.

**Notes:** Correlation between cardiac function and age in DMD or BMD patients based on  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI images. Correlation between SRS and aging in DMD (A) and BMD (B). Correlation between LVEF and aging in DMD (C) and BMD (D). Correlation between EDVI (E) or ESVI (F) and aging in DMD.

**Abbreviations:** DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy;  $^{99}\text{Tc}^{\text{m}}$ -MIBI G-MPI, technetium 99m-methoxyisobutylisonitrile gated myocardial perfusion imaging; SRS, summed rest score; LVEF, left ventricular ejection fraction; EDVI, end-diastolic volume index; ESVI, end-systolic volume index.

and age in BMD patients. We considered this negative result to be due to an insufficient sample size in our BMD population ( $n=14$ ).

Dystrophin-deficient myocardium is more vulnerable to pressure overload *in vivo* than normal myocardium.<sup>20–22</sup>

The inferior wall of the left ventricle should be the most vulnerable site for myocardial perfusion deficiency and cardiac damage because wall stress in this location is greater than other parts of the left ventricle.<sup>23</sup> In addition, the apex of the left ventricle is the second vulnerable site for cardiac

damage because it contains the most abundant amount of myocardial cells, which is rich in dystrophin protein.<sup>24,25</sup> Although <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI images revealed the presence of cardiac damage in almost every left ventricular wall and segment of the left ventricle in this study, the most severe damage was present in the interior wall and apex. Less severe, but notable cardiac damage also existed in apical, apical inferior, and apical anterior areas in DMD patients and in the mid-inferior and apical inferior areas in BMD patients. In the current study, we found a higher detection rate of heart failure in BMD patients (21.4%) than DMD patients (1.3%), suggesting a potential value of <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI in the early detection of cardiac dysfunction in BMDs, which had rarely been reported previously.<sup>17,26</sup> The <sup>99</sup>Tc<sup>m</sup>-MIBI examination has been widely used in other cardiovascular diseases, including coronary artery disease.<sup>27</sup> Ciccone et al<sup>27</sup> used <sup>99</sup>Tc<sup>m</sup>-MIBI in myocardial stress-rest testing in parallel with echocardiography and confirmed the value of the former in diagnosing myocardial function. Therefore, with the maturation of <sup>99</sup>Tc<sup>m</sup>-MIBI technology, the application of such examinations in less common diseases (DMD and BMD) is practical and promising based on its application in other common diseases. Several studies have shown that glucocorticoid therapy can alleviate DMD progression.<sup>28,29</sup> Therefore, we also did a follow-up study using <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI to evaluate the effect of early intervention with glucocorticoid therapy in preventing cardiac damage. We found a significant improvement in myocardial perfusion in the hormone therapy group compared with the untreated group or compared with the baseline level without hormone therapy. It has been reported that low-dose hormone treatment could increase muscle cell regeneration, induce muscle formation, and improve motor function.<sup>30,31</sup> Thus, early intervention with hormone therapy could have a beneficial effect for patients with DMD. In addition, intravenous glucocorticoid treatment (0.75 mg/kg/d) can reduce ventricular load, slow progression of cardiomyopathy, and postpone ventricular dysfunction.<sup>31</sup> We also found that <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI is a stable technique with highly reproducible features, easier postprocedure evaluation, and can provide dynamic observation of the cardiac pathogenesis progression;<sup>28,29,32</sup> however, the long-term effect of glucocorticoids on cardiac structure and function needs further investigation.

There were several limitations in this study that should be mentioned. First, this was a single-center, cross-sectional, small-scale clinical study. Although the power calculation showed that a sufficient sample size was included in this study to obtain a statistically convincing result, a large-scale study further investigating the early diagnostic

value of <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI is needed to verify the findings of the current study. Second, although we have shown that cardiac perfusion deficiency change on <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI manifested earlier than cardiac dysfunction, as shown by standard examination echocardiography, we were not able to distinguish how early in the development of DMD and BMD the <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI would exhibit an advantage versus echocardiography. When to suggest a <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI examination for DMD and BMD patients and what are the benefits from early diagnosis remain to be addressed in a further study.

## Conclusion

<sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI in the assessment of myocardial damage is a suitable method for early evaluation of cardiomyopathy in patients with DMD and BMD, which was first reported in the latter population. <sup>99</sup>Tc<sup>m</sup>-MIBI G-MPI could also serve as a method for evaluating the progression and prognosis of dystrophinopathy.

## Acknowledgments

The authors would like to thank Drs Qingbao Tian, Lingge We, and Zhe Zhao for critical comments and valuable suggestions. This work was supported by the grant from the Third Hospital of Hebei Medical University and the Public Health Department of Hebei Medical University.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Emery AE. The muscular dystrophies. *Lancet*. 2002;359:687–695.
- Jennekens FG, ten Kate LP, de Visser M, Wintzen AR. Diagnostic criteria for Duchenne and Becker muscular dystrophy and myotonic dystrophy. *Neuromuscul Disord*. 1991;1:389–391.
- Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. *J Neurol Sci*. 1991;102:190–196.
- Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. *Circ Cardiovasc Imaging*. 2011;4:67–76.
- Finsterer J, Stollberger C. The heart in human dystrophinopathies. *Cardiology*. 2003;99:1–19.
- Cox GF, Kunkel LM. Dystrophies and heart disease. *Curr Opin Cardiol*. 1997;12:329–343.
- Naruse H, Miyagi J, Arai T, Ohyanagi M, Iwasaki T, Jinnai K. The relationship between clinical stage, prognosis and myocardial damage in patients with Duchenne-type muscular dystrophy: five-year follow-up study. *Ann Nucl Med*. 2004;18:203–208.
- Kumita S, Cho K, Nakajo H, et al. Clinical applications of ECG-gated myocardial perfusion SPECT. *J Nippon Med Sch*. 2006;73:248–257.
- Fu P, Hu L, Sinzinger J, Huang J, Liu X. Assessment of cardiac abnormalities in Duchenne's muscular dystrophy by (99m)Tc-MIBI gated myocardial perfusion imaging. *Hell J Nucl Med*. 2012;15:114–119.
- Sun Y, Ma P, Bax JJ, et al. 99mTc-MIBI myocardial perfusion imaging in myocarditis. *Nucl Med Commun*. 2003;24:779–783.



11. Barker S, Lees DM, Wood EG, Corder R. Inhibitory effect of adrenomedullin on basal and tumour necrosis factor alpha-stimulated endothelin-1 synthesis in bovine aortic endothelial cells is independent of cyclic AMP. *Biochem Pharmacol.* 2002;63:149–156.
12. Mosteller RD. Simplified calculation of body-surface area. *N Engl J Med.* 1987;317:1098.
13. Cerqueira MD, Weissman NJ, Dilsizian V, et al. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation.* 2002;105:539–542.
14. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. *J Am Coll Cardiol.* 1995;26:639–647.
15. Romfh A, McNally EM. Cardiac assessment in duchenne and becker muscular dystrophies. *Curr Heart Fail Rep.* 2010;7:212–218.
16. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. *J Am Coll Cardiol.* 2000;35:569–582.
17. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int J Cardiol.* 1990; 26:271–277.
18. Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. *Am Heart J.* 1996;132: 642–647.
19. Nagamachi S, Inoue K, Jinnouchi S, et al. Cardiac involvement of progressive muscular dystrophy (Becker type, Limb-girdle type and Fukuyama type) evaluated by radionuclide method. *Ann Nucl Med.* 1994;8:71–74.
20. Lapidus KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. *Circ Res.* 2004;94:1023–1031.
21. Colan SD. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs. *Circulation.* 2005;112:2756–2758.
22. Kamogawa Y, Biro S, Maeda M, et al. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. *Cardiovasc Res.* 2001; 50:509–515.
23. Perloff JK, Henze E, Schelbert HR. Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. *Circulation.* 1984;69:33–42.
24. Ervasti JM, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. *Int Rev Cytol.* 2008;265:191–225.
25. Jung C, Martins AS, Niggli E, Shirokova N. Dystrophic cardiomyopathy: amplification of cellular damage by Ca<sup>2+</sup> signalling and reactive oxygen species-generating pathways. *Cardiovasc Res.* 2008;77:766–773.
26. Townsend D, Daly M, Chamberlain JS, Metzger JM. Age-dependent dystrophin loss and genetic reconstitution establish a molecular link between dystrophin and heart performance during aging. *Mol Ther.* 2011;19:1821–1825.
27. Ciccone MM, Niccoli-Asabella A, Scicchitano P, et al. Cardiovascular risk evaluation and prevalence of silent myocardial ischemia in subjects with asymptomatic carotid artery disease. *Vasc Health Risk Manag.* 2011;7:129–134.
28. Miura P, Andrews M, Holcik M, Jasmin BJ. IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells. *PLoS One.* 2008;3:e2309.
29. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, Knudson JC, Jasmin BJ, Megency LA. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. *FASEB J.* 2004;18:1937–1939.
30. Beenakker EA, Fock JM, Van Tol MJ, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. *Arch Neurol.* 2005;62:128–132.
31. Parreira SL, Resende MB, Zanoteli E, Carvalho MS, Marie SK, Reed UC. Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy. *Arq Neuropsiquiatr.* 2010;68:683–688.
32. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. *Neuromuscul Disord.* 2008;18:365–370.

## Therapeutics and Clinical Risk Management

### Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS,

Submit your manuscript here: <http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

Dovepress

EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.